Archive

Genitourinary Cancers Symposium Daily News Archive

The Genitourinary Cancers Symposium Daily News is the official news source for the Genitourinary Cancers Symposium, providing expert perspectives on controversial topics and session highlights. Articles include physician-authored “Expert Editorials” on current clinical issues in oncology, interviews with Meeting attendees, and recaps of key sessions and presentations. Content is current as of the Meeting date and may not reflect the most recent data.


February 27, 2017

Some of the best research presented during the 2017 GU Cancers Symposium featured genomics, molecular subtyping, and new settings for existing drugs.

Read more

February 18, 2017

Circulating tumor DNA illuminates the genomic landscape of mRCC and highlights potential resistance mechanisms.

Read more

February 18, 2017

Computer-assisted response evaluation could reduce errors and time spent in assessing tumor response in mRCC.

Read more

February 18, 2017

Active surveillance is a safe option for selected patients with small renal masses, according to DISSRM registry study.

Read more

February 17, 2017

Novel phase III trial finds single cycle of BEP can reduce exposure, prevent most recurrences in testicular cancer.

Read more

February 17, 2017

After a median 10 years of follow-up, the BC2001 trial confirmed that adding chemotherapy to RT improves salvage cystectomy rate, locoregional control, and bladder cancer–specific survival over RT alone in muscle-invasive bladder cancer.

Read more

February 17, 2017

Although BCG remains the primary therapy for patients with NMIBC, many patients have disease that is resistant to this treatment or relapses. Optimal treatment for patients with what is now considered BCG-unresponsive NMIBC remains to be established.

Read more

February 17, 2017

ASCO and NCCN announce a joint collaboration to publish practical clinical guidance on the management of side effects caused by immunotherapy.

Read more

February 16, 2017

Prostate cancer can be subtyped based on cell of origin, into luminal A, luminal B, and basal cell subtypes, according to a new study (Abstract 3). Luminal B prostate cancer has the poorest prognosis, but also derives the most benefit from ADT.

Read more

February 16, 2017

Adding mitoxantrone/prednisone to ADT in patients with high-risk prostate cancer who underwent prostatectomy increased the risk of leukemia and did not improve overall or prostate cancer–specific survival in a randomized phase III trial.

Read more

February 16, 2017

Experts discussed differences in active surveillance guidelines in Canada, the United Kingdom, and the United States and how genomic tests and imaging play a role in this disease management strategy.

Read more
February 13, 2017

Experts review the current research and questions regarding the optimal perioperative strategy for the treatment of renal cell carcinoma.

Read more
February 7, 2017

The Genitourinary Cancers Symposium Clinical Corner allows expert physicians to answer questions posed by an attendee during previous Best of ASCO Meetings. 

Read more
February 7, 2017

The ASCO Daily News podcast is dedicated to providing ASCO members and meeting attendees more of the high-quality information they’ve come to expect from the Daily News.

Read more
February 9, 2017

At the present time, genetic evaluation guidelines for prostate cancer primarily focus on BRCA1 and BRCA2 testing. The overall risk of prostate cancer has been reported up to 3.8-fold for men who carry BRCA1 mutations and up to 8.6-fold for men who carry BRCA2 mutations.

Read more

February 9, 2017

Dr. Mehmet Asim Bilen discusses why the GU Cancers Symposium is an important meeting and the sessions he’s looking forward to attending this year.

Read more

February 9, 2017

Dr. Matthew Milowsky will give the urothelial carcinoma year in review lecture at the 2017 GU Symposium. He will focus on developments in immuno-oncology in metastatic urothelial cancer.

Read more

February 9, 2017

During his keynote lecture, Dr. Lawrence H. Einhorn will talk about risk stratification, clinical management, and late complications of chemotherapy for testicular cancer.

Read more

February 9, 2017

Dr. Marston Linehan will discuss genetic conditions with predisposition to RCC and trials in patients with genetically defined familial RCC.

Read more

February 9, 2017

Dr. Josephine Kang, a radiation oncologist with Weill Cornell Medicine, discusses her plans for the GU Cancers Symposium.

Read more